Cambridge Opens Its Doors: A Week of Innovation at the Home of UK Life Sciences
The buzzing Cambridge Wide Open annual event returns in June, this time as a week-long interactive festival showcasing Cambridge’s pioneers, the companies of the future, and opening the offices and workspaces that make up one of the world’s most vibrant ecosystems.
Building on the momentum of the last two Cambridge Wide Open Days, the event will run from 9 - 13th June 2025, offering an immersive experience to global investors, ecosystem CEO’s and employees, sci-tech enthusiasts, policymakers, academics, and curious residents alike.
The Cortes-Ciriano group studies the mutational processes and mechanisms of genome instability underpinning tumourigenesis, immune escape, and drug response through the analysis of high-throughput sequencing data from clinical samples. The group is also leading the development of novel approaches for early cancer detection using long-read sequencing. More information about the group can be found here.
Your role
The Cortes-Ciriano group studies the mutational processes and mechanisms of genome instability underpinning tumourigenesis, immune escape, and drug response through the analysis of high-throughput sequencing data from clinical samples. The group is also leading the development of novel approaches for early cancer detection using long-read sequencing. More information about the group can be found here.
Your role
Key Themes: Reframing Food Waste
Why Attend?
Can innovative freezing turn food waste into opportunity? Discover why frozen is the ‘hottest’ sustainability focus in 2025. Mitch Lee – Podcast Host & Senior NAM PACK’D explores how the world’s most wasted foods are being reframed.
You’ll also experience a tasting session with sensational plant-based goodies.
This is a FREE event – come to learn, taste and discuss!
Key Themes: The Transformative Role of AI in Food and Beverage Innovation
Why Attend?
Join Adam Starkey, founder of Green Gourmet Ltd and Managing Director of Panelitix.ai, for an insightful lunch and learn session exploring the intersection of AI and food innovation. Discover how Adam’s pioneering work is helping businesses leverage AI for competitive advantage and gain a glimpse into the technologies shaping the future of food and beverage innovation.
Key Themes: Food as Medicine and the Power of Culinary Medicine
Why Attend?
Join Dr Rupy Aujla, founder of The Doctor’s Kitchen, for an inspiring lunch and learn session exploring the transformative concept of food as medicine. A Sunday Times bestselling author and TV personality, Dr Rupy is on a mission to revolutionise how we think about food and its role in health.
Key Themes: Revolutionising Soft Drinks and Non-Alcoholic Spirits
Why Attend?
Join Julian Ebbutt, Managing Director of Alfresco Drinks, for a listen, lunch, and slurp session dedicated to innovation in the drinks industry. With over 30 years of experience in hospitality, Julian has driven the success of Alfresco Drinks by creating private-label soft drinks for brands like Pret a Manger, Itsu, Leon Restaurants, and TGI Fridays, as well as introducing award-winning non-alcoholic spirits.
Key Themes: Bringing Malaysian Cuisine to the World
Why Attend?
Join Mariae Hackett, founder of Dapur Mariae, for a live cooking and tasting demo that will transport you to the heart of Malaysia. Discover how Mariae transitioned from a three-decade career in healthcare to creating award-winning sauces, now making waves in Co-op and Selfridges.
Experience the vibrant flavours of Malaysian cuisine firsthand, and hear Mariae’s inspiring story of passion, perseverance, and her mission to make Malaysian food accessible to everyone.
Coulter Partners successfully completed a search assignment for Altimmune Inc. (Nasdaq: ALT), and is pleased to announce the placement of biopharmaceutical industry executives Teri Lawver and Jerry Durso to its Board of Directors.
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications.